TELVAS H80/12.5 10S

About

Telvas H80/12.5 combines Telmisartan (an angiotensin II receptor blocker) and Hydrochlorothiazide (a thiazide diuretic). Telmisartan works by blocking the effects of angiotensin II, a potent vasoconstrictor, leading to relaxation of blood vessels and a reduction in blood pressure. Hydrochlorothiazide increases the excretion of sodium and water by the kidneys, which further reduces blood volume and blood pressure. This synergistic action provides a more potent antihypertensive effect than either drug alone, making it effective for patients whose blood pressure is not adequately controlled by monotherapy.

This combination therapy is indicated for the treatment of essential hypertension. By targeting different mechanisms involved in blood pressure regulation, Telvas H80/12.5 offers comprehensive control, helping to reduce the risk of cardiovascular events such as stroke and heart attack. The fixed-dose combination simplifies treatment regimens and can improve patient adherence. Regular monitoring of blood pressure and electrolyte levels is important during treatment to ensure efficacy and safety.

Uses

• Treatment of essential hypertension
• When monotherapy with Telmisartan or Hydrochlorothiazide is insufficient
• Achieving optimal blood pressure control
• Reducing the risk of cardiovascular morbidity and mortality

Directions For Use

Take this tablet orally once daily, with or without food, as directed by your healthcare provider.

Benefits

• Provides enhanced blood pressure reduction
• Combines two complementary mechanisms of action
• Effective for patients not controlled by monotherapy
• Reduces the risk of major cardiovascular events
• Convenient once-daily dosing
• Improves patient adherence to treatment

Side Effects

• Dizziness
• Headache
• Fatigue
• Hypotension (low blood pressure)
• Electrolyte imbalances (e.g., hypokalemia, hyperkalemia)
• Nausea
• Diarrhea
• Muscle cramps
• Gout exacerbation
• Renal dysfunction
• Cough (less common than with ACE inhibitors)
• Photosensitivity

Safety Measures

• Alcohol - Alcohol can potentiate the hypotensive effects of this medication, increasing the risk of dizziness and orthostatic hypotension. Limit alcohol intake.
• Pregnancy - Telvas H80/12.5 is contraindicated during pregnancy, especially in the second and third trimesters, due to the risk of fetal injury or death from the ARB component.
• Breastfeeding - Not recommended during breastfeeding as both Telmisartan and Hydrochlorothiazide are excreted in breast milk and may harm the infant.
• Liver - Use with caution in patients with hepatic impairment. Hydrochlorothiazide can precipitate hepatic coma in severe liver disease. Dose adjustment may be necessary.
• Kidney - Contraindicated in anuria. Use with caution in severe renal impairment; monitor renal function and electrolytes closely. Dose adjustment may be required.
• Lung - While generally safe, Hydrochlorothiazide can rarely cause acute respiratory distress syndrome (ARDS). Patients with pre-existing lung conditions should be monitored.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.